Japan records surprise trade deficit in July as exports weaken further
On Monday, Cantor Fitzgerald reiterated its Overweight rating on Avidity Biosciences Inc . (NASDAQ:RNA) with a maintained price target of $96.00. Currently trading at $31.60, the company commands a market capitalization of $3.8 billion. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $48 to $96, suggesting significant upside potential. Avidity Biosciences is advancing in the development of potential new therapies for facioscapulohumeral muscular dystrophy (FSHD), a condition affecting approximately 30,000 patients in the United States. The company is making progress with its Phase 3 trial of del-brax, a therapy designed to reduce muscle loss.
According to Cantor Fitzgerald, regulatory discussions for the Phase 3 trial are nearly complete, and Avidity Biosciences is on schedule to initiate the study in the second quarter. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 15.73, providing adequate resources for trial advancement. The pivotal protocol is nearing finalization, and the company is starting to engage trial sites for participation. While the primary endpoint for the trial has not been disclosed, there is a shift among key opinion leaders towards whole body endpoints, such as the "10M walk/run" or "time to up and go," over the previously used reachable workspace measurements.
Enrollment for the FORTITUDE Cohort C is also advancing, with a high level of interest and a backlog of patients eager to participate. Despite initial enrollment being slowed by baseline MRI scheduling requirements and strict criteria, the pace is expected to pick up, with the conclusion of enrollment anticipated soon.
Avidity Biosciences is set to present additional data from the FORTITUDE Cohorts A and B at the upcoming FSHD Society International Research Congress, which will be held on June 12-13 in Amsterdam. This presentation will include 12-month follow-up data on 39 patients, featuring evaluations of DUX4 expression through biopsy and serum biomarkers, creatine kinase (CK) levels, early assessments of muscle function, and potentially initial MRI data.
Investors and stakeholders in Avidity Biosciences are observing the company’s progress closely as it moves towards the potential initiation of its Phase 3 trial and the release of further data in the coming months. While the company currently shows an overall "FAIR" financial health score according to InvestingPro, investors seeking deeper insights can access the comprehensive Pro Research Report, which provides detailed analysis of RNA’s financial position, growth prospects, and industry positioning among 1,400+ top US stocks.
In other recent news, Avidity Biosciences has reported promising results from its Phase 1/2 EXPLORE44 trial for del-zota, a potential treatment for Duchenne muscular dystrophy (DMD) targeting exon 44. The trial demonstrated statistically significant improvements in dystrophin production and other biomarkers, with a favorable safety profile. These results have led to a reaffirmation of Buy ratings from both Citi and H.C. Wainwright, with price targets set at $70 and $72, respectively. Citi emphasized the potential for del-zota to establish a commercial foundation in neuromuscular markets, while H.C. Wainwright highlighted the clean safety profile as a positive sign for Avidity’s platform.
Additionally, BMO Capital Markets and Scotiabank (TSX:BNS) have initiated coverage of Avidity Biosciences, assigning Outperform ratings with price targets of $72 and $70. BMO Capital expressed confidence in Avidity’s strategic direction, noting the company’s potential leadership in treating neuromuscular disorders. Scotiabank’s analysis pointed to the company’s promising portfolio, which includes del-zota, del-desiran for myotonic dystrophy type 1 (DM1), and del-brax for facioscapulohumeral muscular dystrophy (FSHD), as attractive investment opportunities.
The company is preparing for a Biologics License Application (BLA) submission for del-zota by the end of 2025, with potential approval anticipated in 2026. Avidity Biosciences has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA for del-zota, signaling a favorable regulatory path. These developments have positioned Avidity Biosciences as a notable player in the biotech sector, with significant interest from investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.